Cargando…

Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease

OBJECTIVE: Surfactant protein D (SP-D) is considered a serum biomarker of various forms of interstitial lung disease (ILD). In this study, we examined the utility of SP-D as a predictive biomarker for mortality in patients with ILD associated with polymyositis/dermatomyositis (PM/DM) using large-sca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaieda, Shinjiro, Gono, Takahisa, Masui, Kenichi, Nishina, Naoshi, Sato, Shinji, Kuwana, Masataka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289364/ https://www.ncbi.nlm.nih.gov/pubmed/32525903 http://dx.doi.org/10.1371/journal.pone.0234523

Ejemplares similares

Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease
por: Nishina, Naoshi, et al.
Publicado: (2020)

Mortality Risk Stratification Using Cluster Analysis in Patients With Myositis-Associated Interstitial Lung Disease Receiving Initial Triple-Combination Therapy
por: Gono, Takahisa, et al.
Publicado: (2022)

Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Physical Dysfunction after Treatment in Polymyositis and Dermatomyositis: An Observational Study of Physical Dysfunction with Myositis in Japan
por: Kawasumi, Hidenaga, et al.
Publicado: (2016)

Tertiary lymphoid structures in the primary tumor site of patients with cancer-associated myositis: A case–control study
por: Kadota, Hiroko, et al.
Publicado: (2023)

Abatacept downregulates Fcγ receptor I on circulating monocytes: a potential therapeutic mechanism in patients with rheumatoid arthritis
por: Fukue, Ryosuke, et al.
Publicado: (2022)

Recent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies
por: Kawasumi, Hidenaga, et al.
Publicado: (2015)

Myositis interstitial lung disease and autoantibodies
por: Chaudhry, Shire, et al.
Publicado: (2023)

Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations
por: Aoyama, Junichi, et al.
Publicado: (2019)

Management of Myositis-Associated Interstitial Lung Disease
por: Fujisawa, Tomoyuki
Publicado: (2021)

“Management of myositis associated interstitial lung disease”
por: Thong, Lorraine, et al.
Publicado: (2023)

Prognostic Factors for Myositis-Associated Interstitial Lung Disease
por: Fujisawa, Tomoyuki, et al.
Publicado: (2014)

Analytic Morphomics in Myositis-Related Interstitial Lung Disease
por: O’Mahony, Alexander T., et al.
Publicado: (2023)

Significance of Myositis Autoantibody in Patients with Idiopathic Interstitial Lung Disease
por: Song, Ju Sun, et al.
Publicado: (2015)

Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders
por: Kuwana, Masataka, et al.
Publicado: (2021)

IgG4-Related Disease without Overexpression of IgG4: Pathogenesis Implications
por: Nishina, Naoshi, et al.
Publicado: (2012)

Rheumatoid factor is correlated with disease activity and inflammatory markers in antineutrophil cytoplasmic antibody-associated vasculitis
por: Watanabe, Shinji, et al.
Publicado: (2017)

Surfactant gene polymorphisms and interstitial lung diseases
por: Pantelidis, Panagiotis, et al.
Publicado: (2002)

Anti Jo-1 myositis. 'Mechanic's hands' and interstitial lung disease.
por: Taggart, A. J., et al.
Publicado: (2002)

Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis
por: Vojinovic, Tamara, et al.
Publicado: (2020)

High-Resolution CT Findings of Myositis-Related Interstitial Lung Disease
por: Egashira, Ryoko
Publicado: (2021)

Clinical features and outcomes of patients with myositis associated-interstitial lung disease
por: Karampitsakos, Theodoros, et al.
Publicado: (2023)

A New Method for the Assessment of Myalgia in Interstitial Lung Disease: Association with Positivity for Myositis-Specific and Myositis-Associated Antibodies
por: Sambataro, Gianluca, et al.
Publicado: (2022)

The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis
por: Tansley, Sarah L., et al.
Publicado: (2020)

Lung transplantation for interstitial lung disease in idiopathic inflammatory myositis: A cohort study
por: Rivière, Amélie, et al.
Publicado: (2022)

In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype
por: Chinoy, Hector, et al.
Publicado: (2006)

IL-6, IL-8, and IL-10 Are Associated with Hyperferritinemia in Rapidly Progressive Interstitial Lung Disease with Polymyositis/Dermatomyositis
por: Kawasumi, Hidenaga, et al.
Publicado: (2014)

Asymptomatic necrotizing myositis in a young male with progressive interstitial lung disease
por: Baah, Samantha, et al.
Publicado: (2021)

Myositis-Related Interstitial Lung Disease: A Respiratory Physician’s Point of View
por: Waseda, Yuko
Publicado: (2021)

Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases
por: Chen, Xianqiu, et al.
Publicado: (2021)

Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease
por: Avouac, Jérôme, et al.
Publicado: (2020)

Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
por: Shirai, Yuichiro, et al.
Publicado: (2021)

Surfactant Lipidomics in Healthy Children and Childhood Interstitial Lung Disease
por: Griese, Matthias, et al.
Publicado: (2015)

Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease
por: Moll, Sofia A., et al.
Publicado: (2020)

Assessment of Optimal Screening Tests for the Detection of an Inflammatory Myositis-associated Interstitial Lung Disease
por: Castillo, Sonia, et al.
Publicado: (2020)

Interstitial lung disease is a dominant feature in patients with circulating myositis-specific antibodies
por: Misra, Abhinav K., et al.
Publicado: (2021)

Prevalence and clinical associations of myositis antibodies in a large cohort of interstitial lung diseases
por: Moll, Sofia A., et al.
Publicado: (2022)

Interstitial lung disease associated with inflammatory myositis: Autoantibodies, clinical phenotypes, and progressive fibrosis
por: Ceribelli, Angela, et al.
Publicado: (2023)

Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases
por: Kuwana, Masataka, et al.
Publicado: (2022)

Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
por: Brown, Kevin K., et al.
Publicado: (2022)

Development of Necrotizing Myopathy Following Interstitial Lung Disease with Anti-signal Recognition Particle Antibody
por: Kusumoto, Tatsuya, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ko7d3m89o6ssnv98s2e6d15f6k